Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The EHA abstract, submitted by Simona Raso, reports that 2 out of 3 Thalassemia patients treated with EGT’s autologous CD34+ cells have sustained dramatic reduction in blood transfusions after 8 and 5 years, respectively.
Lead Product(s): Autologous CD34+ cells,TNS9.3.55
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Memorial Sloan Kettering Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2021